# Neuphoria Therapeutics Inc. (NEUP)

Source: https://www.quantisnow.com/company/NEUP
Generated: 2026-11-15T05:49:25.838Z

- Ticker: NEUP
- Exchange: NASDAQ
- Sector: Health Care
- Industry: Biotechnology: Pharmaceutical Preparations
- IPO year: 2021
- SEC CIK: 0001191070

## Latest NEUP news and filings

- 2026-10-23 12:00 UTC [SEC Form 8-K] [SEC Form 8-K filed by Neuphoria Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-8-k-filed-by-neuphoria-therapeutics-inc-6755882)
- 2026-09-18 21:12 UTC [SEC Form DEFA14A] [SEC Form DEFA14A filed by Neuphoria Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-defa14a-filed-by-neuphoria-therapeutics-inc-6720831)
- 2026-09-18 20:34 UTC [SEC Form DEFA14A] [SEC Form DEFA14A filed by Neuphoria Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-defa14a-filed-by-neuphoria-therapeutics-inc-6720699)
- 2026-09-18 20:33 UTC [SEC Form DEF 14A] [SEC Form DEF 14A filed by Neuphoria Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-def-14a-filed-by-neuphoria-therapeutics-inc-6720695)
- 2026-09-18 20:10 UTC [SEC Form 10-K] [SEC Form 10-K filed by Neuphoria Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-10-k-filed-by-neuphoria-therapeutics-inc-6720548)
- 2026-07-23 22:39 UTC [SEC Form DEFA14A] [SEC Form DEFA14A filed by Neuphoria Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-defa14a-filed-by-neuphoria-therapeutics-inc-6647711)
- 2026-07-23 22:37 UTC [SEC Form 8-K] [Neuphoria Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Changes in Control of Registrant, Regulation FD Disclosure, Financial Statements and Exhibits](https://www.quantisnow.com/insight/neuphoria-therapeutics-inc-filed-sec-form-8-k-entry-into-a-6647706)
- 2026-07-23 10:11 UTC [Public Offering] [Scancell and Neuphoria Therapeutics Announce Merger Agreement and Financing](https://www.quantisnow.com/insight/scancell-and-neuphoria-therapeutics-announce-merger-agreement-and-financing-6646025)
- 2026-06-26 20:15 UTC [Neuphoria Responds to the announcement made by London-listed Scancell Holdings plc](https://www.quantisnow.com/insight/neuphoria-responds-to-the-announcement-made-by-london-listed-scancell-holdings-6617364)
- 2026-05-26 20:15 UTC [SEC Form 8-K] [Neuphoria Therapeutics Inc. filed SEC Form 8-K: Other Events](https://www.quantisnow.com/insight/neuphoria-therapeutics-inc-filed-sec-form-8-k-other-events-6572327)
- 2026-05-15 12:33 UTC [SEC Form 10-Q] [SEC Form 10-Q filed by Neuphoria Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-10-q-filed-by-neuphoria-therapeutics-inc-6555986)
- 2026-02-17 20:57 UTC [SEC Form 10-Q] [SEC Form 10-Q filed by Neuphoria Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-10-q-filed-by-neuphoria-therapeutics-inc-6395655)
- 2026-01-21 21:01 UTC [SEC Form 4] [SEC Form 4 filed by Director Wilson David Ian](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-wilson-david-ian-6356024)
- 2026-01-21 21:01 UTC [SEC Form 4] [SEC Form 4 filed by Director Davies Peter Miles Winston](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-davies-peter-miles-winston-6356021)
- 2026-01-21 21:01 UTC [SEC Form 4] [SEC Form 4 filed by Director Fisher Alan](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-fisher-alan-6356018)
- 2026-01-21 21:01 UTC [SEC Form 4] [SEC Form 4 filed by Director Ryan Jane](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-ryan-jane-6356017)
- 2025-12-29 21:33 UTC [Amendment: SEC Form SCHEDULE 13D/A filed by Neuphoria Therapeutics Inc.](https://www.quantisnow.com/insight/amendment-sec-form-schedule-13da-filed-by-neuphoria-therapeutics-inc-6328753)
- 2025-12-18 21:15 UTC [SEC Form 8-K] [Neuphoria Therapeutics Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing](https://www.quantisnow.com/insight/neuphoria-therapeutics-inc-filed-sec-form-8-k-notice-of-delisting-6322196)
- 2025-12-17 21:01 UTC [SEC Form 8-K] [Neuphoria Therapeutics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders](https://www.quantisnow.com/insight/neuphoria-therapeutics-inc-filed-sec-form-8-k-submission-of-matters-6319783)
- 2025-12-08 21:15 UTC [SEC Form DEFA14A] [SEC Form DEFA14A filed by Neuphoria Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-defa14a-filed-by-neuphoria-therapeutics-inc-6307061)
- 2025-12-08 13:00 UTC [Conference Announcement] [Leading Proxy Advisory Firm ISS Recommends that Shareholders Vote the WHITE Proxy Card FOR Both of Neuphoria's Director Nominees](https://www.quantisnow.com/insight/leading-proxy-advisory-firm-iss-recommends-that-shareholders-vote-the-6306202)
- 2025-12-04 21:15 UTC [SEC Form DEFA14A] [SEC Form DEFA14A filed by Neuphoria Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-defa14a-filed-by-neuphoria-therapeutics-inc-6303662)
- 2025-12-04 13:00 UTC [Neuphoria Responds to Lynx1's Revised Indication of Interest at a Reduced Price and Premium](https://www.quantisnow.com/insight/neuphoria-responds-to-lynx1s-revised-indication-of-interest-at-a-6302882)
- 2025-12-01 21:15 UTC [SEC Form DEFA14A] [SEC Form DEFA14A filed by Neuphoria Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-defa14a-filed-by-neuphoria-therapeutics-inc-6297806)
- 2025-12-01 13:00 UTC [Neuphoria Provides Facts, Exposes False Narratives in Response to Lynx1 Fictions](https://www.quantisnow.com/insight/neuphoria-provides-facts-exposes-false-narratives-in-response-to-lynx1-6296886)
- 2025-11-25 21:15 UTC [SEC Form DEFA14A] [SEC Form DEFA14A filed by Neuphoria Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-defa14a-filed-by-neuphoria-therapeutics-inc-6293673)
- 2025-11-24 21:16 UTC [SEC Form DEFA14A] [SEC Form DEFA14A filed by Neuphoria Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-defa14a-filed-by-neuphoria-therapeutics-inc-6291898)
- 2025-11-24 13:09 UTC [SEC Form DEFC14A filed by Neuphoria Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-defc14a-filed-by-neuphoria-therapeutics-inc-6291327)
- 2025-11-24 13:00 UTC [Neuphoria Therapeutics Inc. Sends Letter to Stockholders](https://www.quantisnow.com/insight/neuphoria-therapeutics-inc-sends-letter-to-stockholders-6291056)
- 2025-11-14 21:17 UTC [SEC Form 424B5] [SEC Form 424B5 filed by Neuphoria Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-424b5-filed-by-neuphoria-therapeutics-inc-6280682)
- 2025-11-14 12:34 UTC [SEC Form 10-Q] [SEC Form 10-Q filed by Neuphoria Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-10-q-filed-by-neuphoria-therapeutics-inc-6279006)
- 2025-11-12 11:17 UTC [SEC Form DEFA14A] [SEC Form DEFA14A filed by Neuphoria Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-defa14a-filed-by-neuphoria-therapeutics-inc-6272472)
- 2025-11-12 11:16 UTC [SEC Form PREC-14A] [SEC Form PREC14A filed by Neuphoria Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-prec14a-filed-by-neuphoria-therapeutics-inc-6272466)
- 2025-11-11 12:00 UTC [Neuphoria Announces Initiation of Strategic Review to Maximize Stockholder Value](https://www.quantisnow.com/insight/neuphoria-announces-initiation-of-strategic-review-to-maximize-stockholder-value-6271789)
- 2025-10-30 00:04 UTC [SEC Form DEF 14A] [SEC Form DEF 14A filed by Neuphoria Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-def-14a-filed-by-neuphoria-therapeutics-inc-6250796)
- 2025-10-30 00:06 UTC [SEC Form DEFA14A] [SEC Form DEFA14A filed by Neuphoria Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-defa14a-filed-by-neuphoria-therapeutics-inc-6250795)
- 2025-10-27 20:29 UTC [Mergers & Acquisitions] [Neuphoria Therapeutics Adopts Limited-Duration Stockholder Rights Plan to Protect Integrity of Process](https://www.quantisnow.com/insight/neuphoria-therapeutics-adopts-limited-duration-stockholder-rights-plan-to-protect-integrity-6246180)
- 2025-10-27 20:19 UTC [SEC Form 8-K] [Neuphoria Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Other Events, Financial Statements and Exhibits](https://www.quantisnow.com/insight/neuphoria-therapeutics-inc-filed-sec-form-8-k-entry-into-a-6246132)
- 2025-10-27 13:40 UTC [SEC Form 424B5] [SEC Form 424B5 filed by Neuphoria Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-424b5-filed-by-neuphoria-therapeutics-inc-6245690)
- 2025-10-23 23:49 UTC [Insider Buy] [Large owner Lynx1 Capital Management Lp bought $3,283,108 worth of shares (639,110 units at $5.14) (SEC Form 4)](https://www.quantisnow.com/insight/large-owner-lynx1-capital-management-lp-bought-3283108-worth-of-6243906)

## More

- Live page with ratings, short volume, options and peers: https://www.quantisnow.com/company/NEUP
- Earnings history: https://www.quantisnow.com/earnings/NEUP
- Dividend history: https://www.quantisnow.com/dividends/NEUP
- Insider transactions: https://www.quantisnow.com/insiders/NEUP
- Options chain: https://www.quantisnow.com/options/NEUP
- SEC 8-K filings only: https://www.quantisnow.com/company/NEUP/8-k
- RSS and alerts for NEUP: https://www.quantisnow.com/docs/rss-feeds.md